Pharma BD Deal Intelligence
Sanofi's $650M acquisition of Protein Sciences bolstered its vaccines pipeline with recombinant flu manufacturing capacity, a modest bolt-on that scored well on strategic fit though the deal carried no disclosed upfront/milestone split and left long-term commercial impact unclear.
Sanofi to acquire Protein Sciences maker of Flublok recombinant influenza vaccine for $650 million upfront plus $100 million in milestones
Sanofi completes the acquisition of Protein Sciences Corporation and its Flublok recombinant protein-based influenza vaccine platform
Sanofi acquires Protein Sciences gaining FDA-approved Flublok quadrivalent recombinant influenza vaccine and BEST manufacturing platform
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi acquired Protein Sciences for $650M + $100M milestones for vaccines biotech.
$5.0B Global Influenza Vaccine Market (2017) · ~170M US Flu Vaccine Doses/Year
Protein Sciences developed Flublok, the only recombinant influenza vaccine using insect cell technology instead of eggs. This eliminated egg-dependent manufacturing constraints.
Sanofi Pasteur, the world's largest flu vaccine maker, acquired Protein Sciences to add recombinant manufacturing. The platform proved valuable for pandemic preparedness.
Sanofi acquired Protein Sciences for $650M + $100M milestones for vaccines biotech.
Significant transaction at $750M. Sanofi acquired Protein Sciences for $650M + $100M milestones for vaccines biotech.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Protein Sciences Corp. (this deal) | 2017 | $650M | 72 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2017 deals · Sanofi SA deals · Infectious Disease deals